Research programme: antimicrobial agents - Agency for Science, Technology and Research/AstraZeneca
Latest Information Update: 25 Nov 2013
At a glance
- Originator Agency for Science, Technology and Research; AstraZeneca
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Gram-negative infections
Most Recent Events
- 04 Nov 2013 Early research in Gram-negative infections in Singapore and United Kingdom (unspecified route)